
Jan Heyckendorf

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9193979/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Swarm Learning for decentralized and confidential clinical machine learning. Nature, 2021, 594, 265-270.	27.8	375
2	Drugâ€fesistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology, 2018, 23, 656-673.	2.3	159
3	Beyond the IFN-Â horizon: biomarkers for immunodiagnosis of infection with Mycobacterium tuberculosis. European Respiratory Journal, 2014, 43, 1472-1486.	6.7	135
4	What Is Resistance? Impact of Phenotypic versus Molecular Drug Resistance Testing on Therapy for Multi- and Extensively Drug-Resistant Tuberculosis. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	83
5	Novel drugs against tuberculosis: a clinician's perspective. European Respiratory Journal, 2015, 45, 1119-1131.	6.7	67
6	Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 1564-1568.	5.6	59
7	Emergence of bedaquiline resistance in a high tuberculosis burden country. European Respiratory Journal, 2022, 59, 2100621.	6.7	48
8	Rapid genomic first- and second-line drug resistance prediction from clinical <i>Mycobacterium tuberculosis</i> specimens using Deeplex-MycTB. European Respiratory Journal, 2021, 57, 2001796.	6.7	47
9	Detailed stratified GWAS analysis for severe COVID-19 in four European populations. Human Molecular Genetics, 2022, 31, 3945-3966.	2.9	46
10	T-Cell Therapy: Options for Infectious Diseases: Table 1 Clinical Infectious Diseases, 2015, 61, S217-S224.	5.8	42
11	Diagnosis and Management of Systemic Endemic Mycoses Causing Pulmonary Disease. Respiration, 2018, 96, 283-301.	2.6	42
12	Characterization of patients with chronic pulmonary aspergillosis according to the new <scp>ESCMID</scp> / <scp>ERS</scp> ECMM and <scp>IDSA</scp> guidelines. Mycoses, 2017, 60, 136-142.	4.0	40
13	Getting Personal Perspectives on Individualized Treatment Duration in Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 374-383.	5.6	39
14	Time to Culture Positivity and Sputum Smear Microscopy during Tuberculosis Therapy. PLoS ONE, 2014, 9, e106075.	2.5	38
15	Perspective for Precision Medicine for Tuberculosis. Frontiers in Immunology, 2020, 11, 566608.	4.8	35
16	Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis. European Respiratory Journal, 2017, 49, 1700742.	6.7	32
17	Detection of transrenal DNA for the diagnosis of pulmonary tuberculosis and treatment monitoring. Infection, 2017, 45, 269-276.	4.7	32
18	Personalized medicine for patients with MDR-TB: TableÂ1 Journal of Antimicrobial Chemotherapy, 2016, 71. 852-855.	3.0	31

JAN HEYCKENDORF

#	Article	IF	CITATIONS
19	Prediction of anti-tuberculosis treatment duration based on a 22-gene transcriptomic model. European Respiratory Journal, 2021, 58, 2003492.	6.7	27
20	Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies. Clinical Microbiology Reviews, 2022, 35, e0022721.	13.6	26
21	Tuberculosis endotypes to guide stratified host-directed therapy. Med, 2021, 2, 217-232.	4.4	24
22	Evaluation of Galactomannan Testing, the Aspergillus-Specific Lateral-Flow Device Test and Levels of Cytokines in Bronchoalveolar Lavage Fluid for Diagnosis of Chronic Pulmonary Aspergillosis. Frontiers in Microbiology, 2018, 9, 2223.	3.5	23
23	Design of Multidrug-Resistant Tuberculosis Treatment Regimens Based on DNA Sequencing. Clinical Infectious Diseases, 2021, 73, 1194-1202.	5.8	21
24	Clofazimine for the treatment of multidrug-resistant tuberculosis. Clinical Microbiology and Infection, 2019, 25, 128-130.	6.0	19
25	Personalized Medicine for Chronic Respiratory Infectious Diseases: Tuberculosis, Nontuberculous Mycobacterial Pulmonary Diseases, and Chronic Pulmonary Aspergillosis. Respiration, 2016, 92, 199-214.	2.6	18
26	Development of a One-Step Probe Based Molecular Assay for Rapid Immunodiagnosis of Infection with M. tuberculosis Using Dried Blood Spots. PLoS ONE, 2014, 9, e105628.	2.5	18
27	Fibrinogen plasma concentration is an independent marker of haemodynamic impairment in chronic thromic thromboembolic pulmonary hypertension. Scientific Reports, 2015, 4, 4808.	3.3	17
28	Relapse-free cure from multidrug-resistant tuberculosis in Germany. European Respiratory Journal, 2018, 51, 1702122.	6.7	17
29	Gene expression signatures identify biologically and clinically distinct tuberculosis endotypes. European Respiratory Journal, 2022, 60, 2102263.	6.7	17
30	Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country. European Respiratory Journal, 2021, 57, 2002544.	6.7	15
31	Rapid molecular diagnostics of tuberculosis resistance by targeted stool sequencing. Genome Medicine, 2022, 14, 52.	8.2	14
32	Perspectives for systems biology in the management of tuberculosis. European Respiratory Review, 2021, 30, 200377.	7.1	13
33	Rapid diagnosis of pulmonary tuberculosis by combined molecular and immunological methods. European Respiratory Journal, 2018, 51, 1702189.	6.7	12
34	Burden and Characteristics of the Comorbidity Tuberculosis—Diabetes in Europe: TBnet Prevalence Survey and Case-Control Study. Open Forum Infectious Diseases, 2019, 6, ofy337.	0.9	12
35	Failing treatment of multidrug-resistant tuberculosis: a matter of definition. International Journal of Tuberculosis and Lung Disease, 2019, 23, 522-524.	1.2	10
36	New World Health Organization Treatment Recommendations for Multidrug-Resistant Tuberculosis: Are We Well Enough Prepared?. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 514-515.	5.6	10

Jan Heyckendorf

#	Article	IF	CITATIONS
37	Tuberculostearic Acid-Containing Phosphatidylinositols as Markers of Bacterial Burden in Tuberculosis. ACS Infectious Diseases, 2022, 8, 1303-1315.	3.8	9
38	Defining Outcomes of Tuberculosis (Treatment): From the Past to the Future. Respiration, 2021, 100, 843-852.	2.6	8
39	Thermostability of IFN-Î ³ and IP-10 release assays for latent infection with Mycobacterium tuberculosis: A TBnet study. Tuberculosis, 2016, 98, 7-12.	1.9	7
40	Intensified adjunctive corticosteroid therapy for CNS tuberculomas. Infection, 2020, 48, 289-293.	4.7	6
41	High-dose isoniazid in the shorter-course multidrug-resistant tuberculosis regimen in the Republic of Moldova. European Respiratory Journal, 2017, 50, 1701340.	6.7	5
42	Lack of evidence of isoniazid efficacy for the treatment of MDR/XDR-TB in the presence of the <i>katG</i> 315T mutation. European Respiratory Journal, 2017, 50, 1701752.	6.7	5
43	Mycobacterium Growth Inhibition Assay of Human Alveolar Macrophages as a Correlate of Immune Protection Following Mycobacterium bovis Bacille Calmette–Guérin Vaccination. Frontiers in Immunology, 2018, 9, 1708.	4.8	5
44	Functional Immune Reconstitution by Interleukin-2 Adjunctive Therapy for HIV/Mycobacterial Co-infection. Emerging Infectious Diseases, 2015, 21, 1685-1687.	4.3	4
45	Changes in taste and smell as an early marker for COVID-19. International Journal of Infectious Diseases, 2020, 99, 8-9.	3.3	4
46	Culture-free proof of Mycobacterium tuberculosis - a new assay for viable bacteria. EBioMedicine, 2020, 62, 103117.	6.1	4
47	Chronic Cough and Severe Weight Loss in a 55-Year-Old Previously Healthy Man. Clinical Infectious Diseases, 2017, 65, 349-351.	5.8	3
48	Serial measurements of transrenal mycobacterial DNA as indicators of the early bactericidal activity (EBA) of antituberculosis drugs. Tuberculosis, 2017, 102, 31-33.	1.9	3
49	Reply: Benefit of the Shorter Multidrug-Resistant Tuberculosis Treatment Regimen in California and Modified Eligibility Criteria. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 1489-1490.	5.6	2
50	An Unexpected Endobronchial Mass Appearing During Bronchoscopy. Chest, 2018, 154, e13-e21.	0.8	1
51	The best of respiratory infections from the 2015 European Respiratory Society International Congress. ERJ Open Research, 2016, 2, 00049-2016.	2.6	0
52	Pulmonary vasculitis due to infection with Mycobacterium goodii: A case report. International Journal of Infectious Diseases, 2021, 104, 178-180.	3.3	0
53	Pathogen-free diagnosis of tuberculosis. Lancet Infectious Diseases, The, 2021, 21, 1066.	9.1	Ο